The International Federation of Head and Neck Oncologic Societies presents



Current Concepts in Head & Neck Surgery & Oncology

Global Continuing Education Program

October 15 – November 1, 2020

TOUR SCHEDULE

After seven very successful World Tour Programs in 2008, 2010, 2012, 2016, 2017, 2018 and 2019, the International Federation of Head and Neck Oncologic Societies is again offering a global continuing medical education program featuring the most respected leaders in the field of Head & Neck surgery and oncology. This worldwide program will cover locations in a sequence (shown below). Future programs will cover other parts of the world. Nations are clustered into regions to offer easy access to as many individuals as possible at each session. The program will provide state-of-art knowledge and explore the frontiers of Head and Neck cancer diagnosis and treatment through introductory lectures, intense interactive discussions with regional specialists through case presentations, and demonstration of operative techniques through video sessions. Ample opportunity for discussion between the local faculty, attendees and the traveling faculty will be provided.







Jatin P. Shah

MD, PhD (Hon.), DSc (Hon.), FACS, FRCS (Hon.), FDSRCS (Hon.), FRACS (Hon.), FRCSDS (Hon.), FRCSI (Hon.) Jatin P. Shah, M.D, holds The Elliott W. Strong Chair in Head and Neck Oncology and chaired the department of Head and Neck Surgery at Memorial Sloan Kettering Cancer Center (MSKCC) for 23 years. He is the Professor of Surgery at Cornell Medical College, New York.

In addition to his superlative patient care activities, Dr. Shah is an international leader in the field of Head and Neck Surgery. He has delivered over 1,500 scientific presentations worldwide, over 80 eponymous lectures, and published more than 600 peer-reviewed articles which have been cited over 49000 times according to Google scholar. His h-index is 126. He has published 14 medical textbooks. His textbook on Head and Neck Surgery and Oncology (now in it's Fifth edition) has been recognized as the best book in Head and Neck Surgery by the British Medical Association and the Royal Society of Medicine.

He has served as the President of The New York Cancer Society, The New York Head and Neck Society, The Society of Head and Neck Surgeons, The North American Skull Base Society and the International Academy of Oral Oncology. He founded The International Federation of Head and Neck Oncologic Societies (IFHNOS) and serves as its CEO. He is listed amongst the Top Doctors in USA directories for 55 times in last 20 years. He was awarded Honorary Fellowships from The Royal College of Surgeons of Edinburgh, London, Ireland and Australia and Honorary PhD degrees from Belgium and Greece, Honorary D.Sc from India, the Blokhin Gold Medal from Russia, Sir William Wilde medal from Ireland, and the Ellis Island Medal of Honor from the US. He was inducted to "Living Legends in Oncology" in India. He has trained hundreds of Residents and Fellows in Head and Neck Surgery and mentored 8 PhD candidates for their doctoral degree.

In recognition of his outstanding efforts to enhance patient care and physician training and education in Head and Neck Surgery, Dr. Shah has received numerous awards from all corners of the world, including an eponymous lecture established in his name by the IFHNOS, an academic symposium in his name at the annual meetings of the American Head and Neck Society, and the Jatin Shah Lectureship and an Endowed Chair established in his name at MSKCC in New York.





Pankaj Chaturvedi

Professor Pankaj Chaturvedi is the Head and Neck Cancer Surgeon and Deputy Director at Tata Memorial Centre, Mumbai. He has been invited as visiting faculty in 44 institutions in 32 countries. He is the editor of the Textbook of Head and Neck Surgery. He is the Associate Editor of the International Journal of Head and Neck Surgery. He has authored more than 200 papers in international peer-reviewed journals. He is the Principal investigator of several pivotal randomized clinical trials.

Dr. Chaturvedi's main area of interest is the prevention and early detection of Oral Cancer. He is the recipient of the prestigious NIH R01 Grant for Research on Tobacco Carcinogenesis. Secretary-General, International Federation of Head Neck Oncologic Societies; Global Coordinator, World Head Neck Cancer Day; Councilor, International Academy of Oral Oncology; Chairman, Oral Cancer Foundation, Indian Dental Association; Founder, Head and Neck Cooperative Oncology Group; Founder, Indian Society of Thyroid Surgeons; Founder, Oral Cancer Task Force; Member, International Advisory Board, American Head and Neck Societies; Secretary, Action Council Against Tobacco – India are some of the feathers that adorn his cap.

He has received several awards - Excellence in Cancer Care Award, 2017; Nana Palkar Smruti Award for Excellence in Patient Care, 2017; Health Award for Excellence in Oncology, 2016; Iconic Leadership Award, World CSR Day, 2016; Sushruta Award, 2015; BMJ Award for Health Advocacy, 2014; Judy Wilkenfield Award, Campaign for Tobacco-Free Kids, 2013; Global Cancer Ambassador, American Cancer Society, 2011; WHO Director - General Award for Leadership in Tobacco Control, 2010; Maxwell Robert Byers Award, American Head and Neck Society, 2010; Outstanding Young Indian Award, 2008.

Dr. Chaturvedi is the founder of Maharashtra Cancer Warriors that is offering voluntary oncology services in 24 district hospitals of Maharashtra. He is the coordinator of the oncology services on Lifeline Express, the world's first cancer hospital on a train. He conceptualized, established and launched India's first Online Oncology Tutorial that is already being employed by several state governments in India. Dr. Chaturvedi has tremendous interest in Public Health issue especially related to tobacco, areca nut and alcohol control. He was invited as a speaker in the United Nation's Summit on Non-Communicable Diseases, 2011 in New York.





Vincent Gregoire

Prof. Vincent Gregoire graduated as a Medical Doctor (MD) in 1987 from the Université Catholique de Louvain, Belgium. He got board certified in Radiation Oncology in Belgium in 1994 and obtained his PhD in Radiation Biology in 1996 after a Fellowship at the Netherlands Cancer Institute, Amsterdam (The Netherlands) and MD Anderson Cancer Center, Houston (USA).

Since his return from the USA, Prof. Gregoire was appointed at the Academic Hospital of the Catholic University of Louvain in Brussels (Belgium) where he was the Director of the Center for Molecular Imaging, Oncology and Radiotherapy; Full Professor in Radiation Oncology and Head of Clinic in the Department of Radiation Oncology. From 1st May 2018, Prof. Vincent Gregoire is the Head of the Radiation Oncology Department at the Léon Bérard Cancer Center, Lyon (France). He coordinates the Head and Neck Oncology Program where the publication of the consensus guidelines for selection and delineation of target volumes brought him worldwide recognition. Besides his clinical activities, Vincent Gregoire has been running a Translational Research Program on tumour microenvironment, on the integration of functional and molecular imaging for treatment planning and on the molecular basis of increased radiosensitivity in HPV-infected cells.

Vincent Gregoire has directed or co-directed 15 PhD theses and has authored or co-authored 254 peer-reviewed publications and 16 book chapters. He has delivered close to 850 abstract presentations, lectures or teaching seminars worldwide, including award lectures such as the IFHNOS KK Ang Lecture in 2014 and the Blair Hesketh BAHNO Memorial Lecture in 2015. He is the member of the Editorial Board of Radiotherapy & Oncology and is a member of numerous scientific societies, including ASTRO and ESTRO, in which he serves on various committees. He has been the President of ESTRO from 2007 to 2009. Vincent Gregoire is the past Vice-President of the board of EORTC, past-Chairman of the Radiation Oncology Group of the EORTC as well as of the Head & Neck Group of the EORTC. Prof. Vincent Gregoire was the Acting Chairman of the ICRU Report Committee on 'Dose prescription, specification and reporting in IMRT'. He has been nominated as the Chairman of ICRU in October 2018. In 2008, he was awarded Honorary Fellow of the British Royal College of Radiology and in 2016 Honorary Fellow of the Irish College of Radiology. In 2014, he received the Breur Award from ESTRO and in 2015, he was awarded Honorary ESTRO Physicist. In 2018, he received the Jens Overgaard Legacy Award from ESTRO.





Robert I. Haddad

Robert I. Haddad, MD, is the Professor of Medicine in Harvard Medical School. He is the Division Chief and Institute Physician of Center of Head and Neck Oncology Program and a member of the Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Dr. Haddad received his medical degree from Saint Joseph University, French Faculty of Medicine and served as an intern and a Resident at St. Luke's Roosevelt Hospital Center, New York. He completed his Fellowship in Haematology / Oncology at Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland.

Dr. Haddad is a member of several professional societies, including the American Society of Clinical Oncology, the American Association for Cancer Research and the American Society for Therapeutic Radiology and Oncology. Dr. Haddad's research is focused on identifying innovative forms of treatment in Head and Neck Cancer. His research activities involve the use of induction chemotherapy for patients with locally advanced Head and Neck Cancer and the development of novel biologic and immunotherapeutic agents for treating locally advanced and metastatic diseases. He has been instrumental in the development, execution and publication of numerous phase II and III trials in Head and Neck Cancer. These trials have led to major advances in Head and Neck Oncology and have resulted in new therapies for patients.

Dr. Haddad is also involved in teaching oncology fellows as well as medical residents and ENT residents through the Dana-Farber Cancer Institute Outpatient Clinic and Brigham and Women's Hospital Inpatient service. He lectures extensively on Head and Neck Cancer at the local, regional, national and international levels and has been invited to lecture in prestigious institutions and at national and international forums. He has presented his work at important scientific meetings such as the American Society of Clinical Oncology (ASCO) and the American Head and Neck Society Meeting (AHNS) and has edited two textbooks on Head and Neck Cancer.

Dr. Haddad has an active role in the National Comprehensive Cancer Network (NCCN) where he participates as a committee member in the Head and Neck Committee and Chair of the Thyroid Cancer Committee. In this capacity, he helps write treatment guidelines. He has authored more than 200 publications related to head and neck cancer.





Jeffrey N. Myers

Dr. Jeffrey N. Myers is Professor and Chair of the Department of Head and Neck Surgery at the University of Texas MD Anderson Cancer Center, where he also holds the Alando J. Ballantyne Distinguished Chair of Head and Neck Surgery. He was the President of the American Head and Neck Society in July 2016 and served through 2017.

Dr. Myers received his medical (MD) and doctoral (PhD) degrees from the University of Pennsylvania School of Medicine and he then completed his residency training in Otolaryngology-Head and Neck Surgery at the University of Pittsburgh. He subsequently completed fellowship training in Head and Neck Surgical Oncology at the University of Texas MD Anderson Cancer Center in 1997, where he has been on the faculty ever since.

Dr. Myers has been at the forefront in the comprehensive genomic characterization of oral cancers and has made seminal contributions to understanding the mechanisms of p53 gain of function mutations in oral cancer progression and metastasis. His continuous and progressive discoveries are fundamental building blocks in the understanding of human cancer. He first reported the comprehensive genomic characterization of Head and Neck Squamous Cell Carcinoma (HNSCC) and developed an algorithm, termed evolutionary action (EAp53), to identify gain of function p53 mutations that has both prognostic and predictive value. Dr. Myers' research revealed the previously unappreciated alterations in Notch cell cycle and p53 pathways in HNSCC which provided important biological insights, are now helping to define new clinical strategies to treat this disease.

Through the continued pre-clinical study of Notch and p53 mutant HNSCC, he and his team identified therapeutic vulnerabilities to PI-3 kinase inhibition and DNA damage repair protein inhibition. These strategies show promise as single agents and are likely to have more efficacy in combination with conventional treatments such as radiation, chemotherapy and/or immunotherapy. Dr. Myers and his team are currently working on translating these pre-clinical observations to look at the safety and efficacy of these targeted treatments in clinical trials.





Richard J. Wong

Dr. Richard J. Wong earned a B.S. in Biology and a B.A. in History at Stanford University in 1990. He attended Harvard Medical School where he earned his M.D in 1994. After completing a General Surgical Internship at the Yale School of Medicine from 1994-95, he trained in Otolaryngology-Head and Neck Surgery at the Harvard Program in Otolaryngology from 1995-1999. He completed a clinical and T32 Research Fellowship in Head and Neck Surgical Oncology at Memorial Sloan-Kettering Cancer Center from 1999-2001 before joining as the full-time faculty in the Department of Surgery.

In 2015, Dr. Wong was appointed as Chief of the Head and Neck Service in the Department of Surgery after having served as the Vice-Chair of Clinical Activities. He is Co-Leader of the Head and Neck Multi-Disciplinary Disease Management Team at Memorial Sloan-Kettering Cancer Center. His clinical expertise is in caring for patients with all types of head and neck malignancies. Dr. Wong has a particular interest in managing patients with aggressive or recurrent thyroid cancer, oral cancer, salivary cancer, and melanoma.

Dr. Wong directs an NIH-funded research laboratory that seeks to elucidate complex relationships between nerves and cancers. He is the Principal Investigator of an R01 grant from the NCI exploring mechanisms of perineural invasion. His laboratory has been previously funded by grants awarded by the NIDCR, the American Society of Clinical Oncology, the American College of Surgeons, the American Head and Neck Society, the Flight Attendant Medical Research Institute. Dr. Wong is the Principal Investigator of an NIH T32 grant supporting the research training of Head and Neck Surgical Oncologists at MSKCC. He also serves as the Site Director for the Cornell / Columbia Otolaryngology Residency program and is committed to the training of residents and fellows.

Dr. Wong's research has been published in a variety of journals, including Journal of Clinical Investigation, Proceedings of the National Academy of Sciences, Journal of the National Cancer Institute, Journal of Clinical Oncology, Journal of Clinical Endocrinology and Metabolism, Clinical Cancer Research, Molecular Cancer Research, Molecular Therapy, International Journal of Cancer, Human Gene Therapy, Cancer Gene Therapy, Neoplasia, Journal of Nuclear Medicine, PLOS One.

WORLD TOUR PROGRAM

Day 1

TIME	ТОРІС	SPEAKER / MODERATOR
08:00 - 08:15 am	Introduction	Jatin Shah
08:15 - 09:30 am	Oral Cancer Panel	Moderator: Pankaj Chaturvedi
08:15 - 08:45 am	Oral Cancer	Jeffrey Myers
08:45 - 09:30 am	Panel Discussion	Jeffrey Myers, Vincent Gregoire, Robert Haddad and 3 Local Faculties
09:30 - 10:00 am	Coffee	
10:00 - 12:30 pm	Thyroid Cancer	Moderator: Vincent Gregoire
10:00 - 10:30 am	Risk Stratified Rx of Primary	Jatin Shah
10:30 - 11:00 am	Treatment of Neck Nodes	Pankaj Chaturvedi
11:00 - 11:30 am	Recurrent Thyroid Cancer	Richard Wong
11:30 - 12:30 pm	Panel Discussion	Jatin Shah, Pankaj Chaturvedi, Richard Wong, Robert Haddad and 3 Local Faculty
12:30 - 01:30 pm	Lunch	
01:30 - 03:00 pm	Multidisciplinary Treatments	Moderator: Jeffrey Myers
01:30 - 02:00 pm	Advances in Radiotherapy: Risk Stratification	Vincent Gregoire
02:00 - 02:30 pm	Advances in Systemic Therapy: Curative and Palliative	Robert Haddad
02:30 - 03:00 pm	Multidisciplinary Panel	Vincent Gregoire, Robert Haddad, Jatin Shah and 3 Local Faculty
03:00 - 03:30 pm	Coffee Break	
03:30 - 04:30 pm	Salivary Tumors	Moderator: Richard Wong
03:30 - 04:00 pm	Surgery for Salivary Tumors	Pankaj Chaturvedi
04:00 - 04:30 pm	Panel Discussion	Pankaj Chaturvedi, Jeffrey Myers, Vincent Gregoire and 3 Local Faculty
04:30 - 06:00 pm	Video Session	Jatin Shah, Richard Wong, Jeffrey Myers and Pankaj Chaturvedi

WORLD TOUR PROGRAM

Day 2

ΤΙΜΕ	ТОРІС	SPEAKER / MODERATOR
08:00 - 09:15 am	Oropharynx Panel	Moderator: Robert Haddad
08:00 - 08:20 am	Surgery	Jeffrey Myers
08:20 - 08:40 am	Radiation Therapy - W/WO Chemo Rx	Vincent Gregoire
08:40 - 09:15 am	Panel Discussion	Jeffrey Myers, Vincent Gregoire, Pankaj Chaturvedi and 3 Local Faculty
09:15 - 10:00 am	Skin Cancer (Melanoma)	Moderator: Jeffrey Myers
09:15 - 09:45 am	Surgical Management	Richard Wong
09:45 - 10:00 am	Panel Discussion	Richard Wong, Jatin Shah, Robert Haddad and 3 Local Faculty
10:00 - 10:30 am	Coffee Break	
10:30 - 12:00 noon	New Therapies / New Technologies Panel	Moderator: Pankaj Chaturvedi
10:30 - 11:00 am	Targeted and Immunotherapy	Robert Haddad
11:00 - 11:30 am	New Technologies in Surgery	Jeffrey Myers
11:30 - 12:00 noon	RT of Tomorrow: Protons and Beyond	Vincent Gregoire
12:00 - 01:00 pm	Lunch	
01:00 - 02:30 pm	Skull Base Tumors Panel	Moderator: Richard Wong
01:00 - 01:45 pm	Skull Base Surgery in 2020	Jatin Shah
01:45 - 02:30 pm	Panel Discussion	Jatin Shah, Jeffrey Myers and 3 Local Faculty
02:30 - 03:00 pm	Coffee Break	
03:00 - 04:00 pm	Stump the Faculty	Moderator: Jatin Shah Faculty: Jeffrey Myers, Richard Wong, Pankaj Chaturvedi, Vincent Gregoire and Robert Haddad
04:00 - 05:00 pm	Video Session	Jatin Shah, Richard Wong, Jeffrey Myers and Pankaj Chaturvedi

